Literature DB >> 24839327

Community-based prevention of hepatitis-B-related liver cancer: Australian insights.

Monica C Robotin1, Melanie Q Kansil2, Mamta Porwal1, Andrew G Penman1, Jacob George3.   

Abstract

PROBLEM: Although most primary hepatocellular cancers (HCCs) are attributable to chronic viral hepatitis and largely preventable, such cancers remain a leading cause of cancer-related mortality wherever chronic hepatitis B is endemic. APPROACH: Many HCCs could be prevented by increasing awareness and knowledge of hepatitis B, optimizing the monitoring of chronic hepatitis B and using antiviral treatments - but there are gaps in the implementation of such strategies. LOCAL
SETTING: The "B Positive" programme, based in Sydney, Australia, is designed to improve hepatitis-B-related health outcomes among immigrants from countries with endemic hepatitis B. The programme offers information about disease screening, vaccination and treatment options, as well as optimized access to care. RELEVANT CHANGES: The B Positive programme has been informed by economic modelling. The programme offers culturally tailored education on chronic hepatitis B to target communities and their health practitioners and regular follow-up through a population-based registry of cases. LESSONS LEARNT: As the costs of screening for chronic hepatitis B and follow-up are relatively low and less than one in every four cases may require antiviral drugs, optimizing access to treatment seems an appropriate and cost-effective management option. The identification and accurate staging of cases and the judicious use of antiviral medications are predicated upon an informed and educated health workforce. As establishing community trust is a lengthy process, delaying the implementation of programmes against chronic hepatitis B until antiviral drugs become cheaper is unwarranted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24839327      PMCID: PMC4007129          DOI: 10.2471/BLT.13.130344

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  12 in total

1.  Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm.

Authors:  J P Moatti; I N'Doye; S M Hammer; P Hale; M Kazatchkine
Journal:  Nat Med       Date:  2003-12       Impact factor: 53.440

Review 2.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

3.  Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.

Authors:  Dilip Ratnam; Anouk Dev; Tin Nguyen; Vijaya Sundararajan; Hugh Harley; Wendy Cheng; Alice Lee; Ferry Rusli; Robert Chen; Sally Bell; Stephen Pianko; William Sievert
Journal:  J Gastroenterol Hepatol       Date:  2012-09       Impact factor: 4.029

4.  Mobilising Pacific people for health: insights from a hepatitis B screening programme in Auckland, New Zealand.

Authors:  Aumea Herman; Chris Bullen; Sitaleki Finau; Malakai Ofanoa
Journal:  Pac Health Dialog       Date:  2006-09

5.  Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.

Authors:  Tin Nguyen; Alexander J V Thompson; Scott Bowden; Catherine Croagh; Sally Bell; Paul V Desmond; Miriam Levy; Stephen A Locarnini
Journal:  J Hepatol       Date:  2010-02-16       Impact factor: 25.083

6.  A comprehensive screening and treatment model for reducing disparities in hepatitis B.

Authors:  Henry Pollack; Su Wang; Laura Wyatt; Chia-Hui Peng; Kejia Wan; Chau Trinh-Shevrin; Kay Chun; Thomas Tsang; Simona Kwon
Journal:  Health Aff (Millwood)       Date:  2011-10       Impact factor: 6.301

7.  The burden of chronic hepatitis B virus infection in Australia, 2011.

Authors:  Jennifer H MacLachlan; Nicole Allard; Vanessa Towell; Benjamin C Cowie
Journal:  Aust N Z J Public Health       Date:  2013-03-20       Impact factor: 2.939

Review 8.  Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management.

Authors:  Man-Fung Yuen
Journal:  J Gastroenterol Hepatol       Date:  2007-04-19       Impact factor: 4.029

Review 9.  The natural history of chronic hepatitis B virus infection.

Authors:  Jean-Pierre Villeneuve
Journal:  J Clin Virol       Date:  2005-12       Impact factor: 3.168

10.  Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic.

Authors:  R G Gish; S L Cooper
Journal:  J Viral Hepat       Date:  2010-12-08       Impact factor: 3.728

View more
  4 in total

Review 1.  A Rapid Review of Interventions to Increase Hepatitis B Testing, Treatment, and Monitoring among Migrants Living in Australia.

Authors:  Vishnupriya Rajkumar; Kahlia McCausland; Roanna Lobo
Journal:  Int J Environ Res Public Health       Date:  2022-05-13       Impact factor: 4.614

2.  Characteristics Associated with Monitoring and Treatment of Chronic Hepatitis B in a Large Cohort of Australian Adults.

Authors:  Wen-Qiang He; Gail V Matthews; Bette Liu
Journal:  Dig Dis Sci       Date:  2021-05-04       Impact factor: 3.487

Review 3.  Community-based hepatitis B screening: what works?

Authors:  Monica C Robotin; Jacob George
Journal:  Hepatol Int       Date:  2014-08-01       Impact factor: 6.047

4.  Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia.

Authors:  Monica C Robotin; Ximena Masgoret; Mamta Porwal; David Goldsbury; Chee Khoo; Jacob George
Journal:  Clin Epidemiol       Date:  2017-12-21       Impact factor: 4.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.